Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

(2021) Chaolin Huang et al.   LANCET

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

(2021) Romina Libster et al.   NEW ENGLAND JOURNAL OF MEDICINE

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

(2020) Junqiang Lei et al.   RADIOLOGY

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia

(2020) Philippe Guilpain et al.   ANNALS OF THE RHEUMATIC DISEASES

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

(2020) Ling Ni et al.   IMMUNITY

Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab

(2020) Jérôme Avouac et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

(2020) Hendrik Schulze-Koops et al.   ANNALS OF THE RHEUMATIC DISEASES

Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al

(2020) Maurizio Benucci et al.   ANNALS OF THE RHEUMATIC DISEASES

Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

(2020) Phil‐Robin Tepasse et al.   BRITISH JOURNAL OF HAEMATOLOGY

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

(2020) Marie Helleberg et al.   JOURNAL OF INFECTIOUS DISEASES

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

(2020) Ayşe Karataş et al.   TRANSFUSION AND APHERESIS SCIENCE

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

(2020) Francesco Passamonti et al.   Lancet Haematology

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease

(2020) Thomas Hueso et al.   BLOOD

COVID-19 length of hospital stay: a systematic review and data synthesis

(2020) Eleanor M. Rees et al.   BMC Medicine

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

(2020) Hajime Yasuda et al.   Clinical Lymphoma Myeloma & Leukemia

SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study

(2020) Andreas Glenthøj et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

(2020) Julio García-Suárez et al.   Journal of Hematology & Oncology

Prolonged SARS-CoV-2 replication in an immunocompromised patient

(2020) Ji Hoon Baang et al.   JOURNAL OF INFECTIOUS DISEASES

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

(2020) Lennard Y W Lee et al.   LANCET ONCOLOGY

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab

(2020) Igor Kos et al.   Frontiers in Oncology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

(2020) Albrecht Betrains et al.   BRITISH JOURNAL OF HAEMATOLOGY

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

(2020) Victoria A. Avanzato et al.   CELL

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

(2020) Teresa Aydillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

(2020) William A. Wood et al.   Blood Advances

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

(2019) Georg Maschmeyer et al.   LEUKEMIA

Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders

(2018) Jean-Jacques Tudesq et al.   AUTOIMMUNITY REVIEWS

B Cells and Progressive Multifocal Leukoencephalopathy: Search for the Missing Link

(2015) Deniz Durali et al.   Frontiers in Immunology

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

(2013) I. Nazi et al.   BLOOD

European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia

(2013) D. Averbuch et al.   HAEMATOLOGICA

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

(2011) O. E. Yri et al.   BLOOD

ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell Differentiation via Induction of the Transcriptional Repressor Bcl6

(2011) Youn Soo Choi et al.   IMMUNITY

Rituximab-Associated Infections

(2010) Juan C. Gea-Banacloche   SEMINARS IN HEMATOLOGY